As part of our series focussing on medicines available in Australia, this review presents updated long-term efficacy and safety data of belzutifan based on follow-up studies of the LITESPARK-004 phase II trial.
Guiding commentary has been provided by Dr Simon Wood, a urological surgeon and renal transplant surgeon. He has served as Director of Urology at Princess Alexandra Hospital in Brisbane for over 10 years. He is the surgical lead for state-wide multidisciplinary networks in hereditary kidney cancer and co-lead of the Kidney Cancer Research Group at the Centre for Kidney Disease Research located at the Translational Research Institute in Brisbane.
Please login below to download this issue (PDF)